Key Takeaways GLUE signed a $5.7B licensing deal with NVS to develop molecular glue degraders for immune diseases.Novartis gains exclusive rights to a QuEEN platform target and options on two preclinical programs.Deal includes $120M upfront, milestone payments and royalties, strengthening Monte Rosa's cash runway.Shares of clinical-stage biotech Monte Rosa Therapeutics (GLUE) rose 44% on Monday after announcing that it had entered into a collaboration deal with pharma giant Novartis (NVS) to develop novel m ...